<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-113657</identifier>
<setSpec>1134-5934</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Desvenlafaxine, a new SNRI for the treatment of major depression: a literature review</dc:title>
<dc:description xml:lang="en">Desvenlafaxine (DESV) is a new antidepressant within the group of serotonin-norepinephrine reuptake inhibitors (SNRI). Various controlled clinical trials have demonstrated its efficacy in the treatment of adult patients with a major depressive disorder. These studies have evaluated the efficacy of DESV in doses that varied between 50 mg and 400 mg/day. However, the therapeutic dose of DESV has been established at 50 mg/ day, with no additional therapeutic benefits being observed at higher doses. The tolerability and safety profile of DESV at this dose is very favourable, a fact that is associated with a minimal impact on the cytochrome P450 system which gives it the additional advantage of a lower risk of pharmacokinetic interactions. This review provides a summary of the pharmacological data of DESV, as well as the pre-clinical and clinical results on its efficacy and safety (AU)</dc:description>
<dc:creator>Cardoner Álvarez, Narcís</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La desvenlafaxina (DESV) es un nuevo antidepresivo incluido entre los inhibidores de la recaptación de serotonina y noradrenalina (IRSN). Distintos ensayos clínicos controlados han demostrado su eficacia en el tratamiento de pacientes adultos con trastorno depresivo mayor. Estos estudios han evaluado la eficacia de la DESV en dosis que oscilan entre 50 y 400 mg/día. No obstante, la dosis terapéutica de DESV se ha establecido en 50 mg/día, sin que se demuestren beneficios terapéuticos adicionales con dosis superiores. Con esta dosis, el perfil de tolerabilidad y seguridad de DESV es muy favorable, hecho que se asocia a un mínimo impacto en el sistema enzimático del citocromo P450, que aporta la ventaja adicional de un bajo riesgo de interacciones farmacológicas. En esta revisión se resumen los datos farmacológicos de DESV y los resultados preclínicos y clínicos sobre su eficacia y su seguridad (AU)</dc:description>
<dc:source>Psiquiatr. biol. (Ed. impr);20(1/2): 2-7, ene.-jun. 2013. ilus</dc:source>
<dc:identifier>ibc-113657</dc:identifier>
<dc:title xml:lang="es">Desvenlafaxina, un nuevo IRSN para el tratamiento de la depresión mayor: revisión de la literatura</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3883^s22056</dc:subject>
<dc:subject>^d3885^s22057</dc:subject>
<dc:subject>^d935^s22079</dc:subject>
<dc:subject>^d3883^s22057</dc:subject>
<dc:subject>^d3885^s22012</dc:subject>
<dc:subject>^d3885^s22032</dc:subject>
<dc:subject>^d935^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3886^s22032</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d3886^s22012</dc:subject>
<dc:subject>^d935^s22044</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d1714^s22045</dc:subject>
<dc:subject>^d1714^s22066</dc:subject>
<dc:subject>^d50302</dc:subject>
<dc:subject>^d33011</dc:subject>
<dc:type>article</dc:type>
<dc:date>201306</dc:date>
</metadata>
</record>
</ibecs-document>
